An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report.
Juan C Falla-MartinezDaniela EspinosaJuan C BaenaLisa X RodriguezLuz F SuaAngela Regina Zambrano HarveyPublished in: Journal of medical case reports (2019)
Osimertinib seems to be a suitable therapy for treatment-naïve patients with sensitizing and resistant compound EGFR mutations. More studies regarding the clinical characteristics of these patients and the appropriate management of this condition are needed to provide the highest standard of care.
Keyphrases
- growth factor
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- palliative care
- prognostic factors
- quality improvement
- advanced non small cell lung cancer
- tyrosine kinase
- peritoneal dialysis
- pain management
- chronic pain